19 November 2026
by Ferdous Al-Faruque

More drugmakers look to standalone medical devices for combo products

ComboProducts_261118_ALF.png
Left to right: Chin-Wei Soo, Porsche Sanders, Alan Stevens, Andrea Gray, Shruti Mistry and James Bertram. (credit: Ferdous Al-Faruque)

BALTIMORE – Drugmakers that want to develop standalone medical devices to be used in combination with their drugs should evaluate the devices’ capabilities and requirements while engaging health authorities early, according to a panel of experts who spoke at the AFDO/RAPS Combination Products Summit on Tuesday.

Early engagement with health authorities can be especially useful in determining the right regulatory pathway, they said.

Early alignment

Porsche Sanders, regulatory group director at Roche subsidiary Genentech, said that pharmaceutical companies are increasingly adopting standalone physical devices to improve patient experiences and differentiate therapies. However, this change requires them to shift from a drug-centric mindset to one that develops capabilities to manage medical devices as well. This this means having an understanding of regulatory pathways and assuming the responsibilities of the legal manufacturer of devices.

While presenting case studies describing how different combination and standalone products come to market in the US and Europe, Sanders said that drugmakers who want to bring a standalone medical device to market should engage with regulatory authorities early to address basic questions, such as which US Food and Drug Administration (FDA) regulatory pathway is best for their product.

"Early alignment is really important here, and this is where the request for designation can be a good tool that the FDA has," said Sanders. Furthermore, she noted that early engagement can help manufacturers determine which FDA product center should be the lead center and identify testing requirements for their product. She added that early engagement can also be an opportunity to speak with multiple offices within an FDA center to ensure alignment on data requirements.

When considering a standalone device in the US, Sanders said manufacturers should consider user and stakeholder alignment, technical considerations, and their labeling strategy.

Similarly, Sanders emphasized that manufacturers should engage with European health authorities early. She noted that notified bodies require a conformity assessment of the quality management system for a CE mark, in addition to the European Medicines Agency's (EMA) drug review.

"Some of us come from pharmaceutical companies that don't have a ton of standalone device expertise," said Sanders. "That's why it is important to have early engagement within your cross-functional teams for what your clinical evaluation should look like, because you may need device endpoints in your clinical study, which we're not as familiar with in combination products."

Notified bodies and EMA

Jara Benke, senior product specialist at TÜV SÜD, noted that pharmaceutical manufacturers with a standalone medical device have to go through two independent reviews, which includes applying for a medical device certification through a notified body. After receiving the certification, she said the EMA can start the drug approval assessment.

"There is no planned interaction between EMA and the notified body during the device certification or the drug approval," said Benke.

Benke, however, noted there is a clinical evaluation consultation procedure (CECP), which is the only interface between EMA and the notified body at the end of the notified body medical device certification process. An independent expert panel is tasked with reviewing the clinical evidence for certain high-risk Class III and Class IIb devices under the Medical Device Regulation (MDR) Article 54, she noted. She also said that the expert panel's focus is to conduct a scientific evaluation of the novel features and clinical procedures of the medical device, as well as to assess the device's clinical and health benefits and risks.

Benke said that the CECP can also be triggered in the postmarket setting if the device's intended purpose changes but noted that a change in the device's indications doesn't automatically trigger the panel.

FDA’s view

Andrea Gray, a biomedical engineering advisor at the FDA's Center for Biologics Evaluation and Research (CBER), said that when the drug and device manufacturers of a combination product are separate entities, they need to consider the product holistically.

"The drug sponsor needs to ensure that the drug quality is preserved when it's used with that specific device, and the device manufacturer needs to make sure that the device performs as intended to deliver that specific drug or type of drug that it's cleared or approved for," said Gray. This means factoring in device considerations into drug quality elements and also factoring drug considerations into device development."

"The device and drug manufacturers need to have robust quality agreements to clearly establish how they will notify each other of changes to the products and also establish how they share data and how they coordinate when issues arise, including sharing postmarket safety information and possibly coordinating root cause investigations," she added. "Because the product labels are dependent on each other, they need to align the regulatory timelines for their separate applications."

In a scenario where the drugmaker wants to develop a combination device in-house, Gray said the manufacturer should consider other operational challenges, such as its design and manufacturing capabilities, and ensure compliance with quality management and postmarket safety reporting requirements for each submission type.

"Another approach is the one-way labeling, that is where the drug is referencing a specific device, but the device is more general labeling, or it could be vice versa," said Gray. "From the device side, if a device manufacturer is pursuing general clearance, then the current expectation is to demonstrate compatibility with at least one already approved drug in a compatible presentation, and the device needs to be validated for the dose, the rate, the route, and the configuration that it's proposed to deliver in line with that drug's labeling."

Gray noted this could be especially challenging for novel device delivery systems, as they likely lack experience delivering a drug and would need to partner with a pharmaceutical manufacturer to pursue a combination product co-development pathway. She said another common scenario is where a drug sponsor seeks a general labeling approach to use an off-the-shelf device for their product.

"For that to be viable, there needs to be careful consideration of the scope of the current cleared or approved intended use and indications for use for those devices," said Gray. "If the proposed use is not covered by the device's cleared or approved intended use or if additional processing is done on the device, like repackaging or repackaging out of its original primary packaging or re-sterilization, then additional data would be needed to bridge any gaps in the risk to support use in the clinical study, and then commercialization might require collaboration with the device manufacturer to update the device's labeling or creating a custom device."

She noted that in all the scenarios she presented, it is critical for manufacturers to provide drug-device compatibility data demonstrating that drug quality isn't adversely affected by the device, and vice versa.

2026 Combination Products Summit